The intercellular content of the three transcobalamins at various stages of normal and leukaemic myleoid cell development

British Journal of Haematology
J ZittounR Zittoun

Abstract

A study of the three serum transcobalamins (TC) in myeloproliferative disorders and acute leukaemia has suggested a granulocyte origin for the three binders; the later stages of this cell line might be releasing 'TC I' and 'TC III' while 'TC II' which is increased in sera from patients with acute myelogenous leukaemia, probably originates at least in part from myeloblasts. The intracellular content of each TC has been studied in normal and leukaemic bone marrow cells after separation on a discontinuous bovine serum albumin gradient. Myeloblasts contain a TC II-like protein almost exclusively but promyelocytes contain a TC I-like protein which increases as the cells mature whilst 'TC II' decreases. A TC III-like binder parallels 'TC I' but appears later and reaches a maximum in the polymorphonuclear cells. In various types of leukaemia, abnormal TC distributions are related either to marrow replacement by the blast cells or to a disorder of the maturation process in the leukaemic cell line.

References

Nov 1, 1975·British Journal of Haematology·J ZittounC Sultan
Dec 1, 1973·British Journal of Haematology·J M EnglandI Chanarin
Feb 1, 1973·British Journal of Haematology·A V HoffbrandK C Das
Dec 1, 1974·Clinical Science and Molecular Medicine·W G CooksleyA S Tavill
Jul 1, 1974·Proceedings of the Society for Experimental Biology and Medicine·L M MeyerA V Hoffbrand
Jan 1, 1968·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·H Wetterqvist, T White
Jan 1, 1968·Scandinavian Journal of Clinical and Laboratory Investigation·U H StenmanR Gräsbeck
Jun 1, 1972·European Journal of Clinical Investigation·M RachmilewitzJ Gross
Dec 1, 1970·The Journal of Clinical Investigation·J CorcinoV Herbert
Mar 1, 1968·Proceedings of the Society for Experimental Biology and Medicine·C H Tan, H J Hansen
Mar 28, 1966·Biochimica Et Biophysica Acta·K Simons, T Weber
Jan 1, 1967·Scandinavian Journal of Haematology·B L Hom
Jan 1, 1967·Scandinavian Journal of Gastroenterology·J MyrenG C Luketic

❮ Previous
Next ❯

Citations

Feb 1, 1994·Annals of Hematology·R ZittounS Ramond
Mar 15, 1988·Clinica Chimica Acta; International Journal of Clinical Chemistry·J van KapelJ Lindemans
Nov 1, 1975·British Journal of Haematology·J ZittounC Sultan
Jan 1, 2013·Journal of Rural Medicine : JRM·Kazuhiro TakahashiKatsu Hirayama
Jan 1, 1983·British Journal of Haematology·J M DaviesJ Fletcher
Aug 26, 1998·Australian Dental Journal·G J Mount, W R Hume
Oct 28, 2006·Clinical Chemistry·Raffick A R BowenMcDonald K Horne
Sep 1, 1978·Scandinavian Journal of Haematology·P Gimsing, E Hippe
Apr 2, 1999·Cancer Detection and Prevention·F BoissonJ P Nicolas

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.